AP NEWS
Click to copy
Press release content from Business Wire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Aerie Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference

May 28, 2019

DURHAM, N.C.--(BUSINESS WIRE)--May 28, 2019--

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present at the Jefferies 2019 Healthcare Conference on Tuesday, June 4, 2019 at 2:30 p.m. Eastern Time in New York, NY. Dr. Anido will provide an Aerie overview and provide a business update.

The presentation will be webcast live and may be accessed by visiting Aerie’s website at http://investors.aeriepharma.com. A replay of the webcast will be available for 10 business days.

About Aerie Pharmaceuticals, Inc.

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Aerie’s first product, Rhopressa ®  (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa ®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rhopressa ®, including the product label, is available at  www.rhopressa.com. Aerie’s second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan ®  (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa ®  and the widely-prescribed PGA (prostaglandin analog) latanoprost, has been approved by the FDA and was launched in the United States in the second quarter of 2019. In clinical trials of Rocklatan ®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rocklatan ®, including the product label, is available at  www.rocklatan.com. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema. More information is available at  www.aeriepharma.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190528005003/en/

CONTACT: Media: Tad Heitmann 949-526-8747;theitmann@aeriepharma.com

Investors: Ami Bavishi 908-947-3949;abavishi@aeriepharma.com

KEYWORD: UNITED STATES NORTH AMERICA NEW YORK NORTH CAROLINA

INDUSTRY KEYWORD: HEALTH OPTICAL PHARMACEUTICAL GENERAL HEALTH

SOURCE: Aerie Pharmaceuticals, Inc.

Copyright Business Wire 2019.

PUB: 05/28/2019 07:30 AM/DISC: 05/28/2019 07:31 AM

http://www.businesswire.com/news/home/20190528005003/en

All contents © copyright 2019 The Associated Press. All rights reserved.